Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.

Biotechnology

Abata Therapeutics

Samantha Singer

Joanne Tzouvalopoulos Beck

Stephen Fair

Leonard Dragone

Sandy Lazzari

Alec Silverman

Amina Abbadi

Ellen Cahir-McFarland

Christina Strange

Cristina Musselli

Cristin Berkey

John Trzupek

The Leadership Team at Abata Therapeutics is responsible for guiding the strategic direction and operational execution of the company. Comprising top executives with expertise in Treg biology and clinical development, they work to align research efforts with business goals, foster innovation in autoimmune treatments, and ensure the effective management of resources to advance promising therapies for conditions like progressive MS, Type 1 Diabetes, and inclusion body myositis.

Leadership Team

Research and Development

Advisory Team

Leadership Team

About

Team members

Other teams at Abata Therapeutics

Research and Development

Advisory Team